Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
13.44
-0.34 (-2.47%)
Jun 20, 2025, 4:00 PM - Market closed
Niagen Bioscience Revenue
Niagen Bioscience had revenue of $30.48M in the quarter ending March 31, 2025, with 37.59% growth. This brings the company's revenue in the last twelve months to $107.93M, up 29.77% year-over-year. In the year 2024, Niagen Bioscience had annual revenue of $99.60M with 19.18% growth.
Revenue (ttm)
$107.93M
Revenue Growth
+29.77%
P/S Ratio
9.54
Revenue / Employee
$1,037,740
Employees
104
Market Cap
1.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Jan 2, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NAGE News
- 2 days ago - Niagen Bioscience to Participate at the Roth 15th Annual London Conference - Business Wire
- 11 days ago - Niagen Bioscience to Participate in the BIO 2025 International Convention - Business Wire
- 11 days ago - Niagen Bioscience: High Conviction, High Expectations - Seeking Alpha
- 13 days ago - Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder - Business Wire
- 18 days ago - Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference - Business Wire
- 6 weeks ago - Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook - Business Wire
- 6 weeks ago - Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - Business Wire